p53 expression as a prognostic determinant in resected distal bile duct carcinoma

A. M. Rijken, G. J A Offerhaus, M. M. Polak, D. J. Gouma, T. M. Van Gulik

Research output: Contribution to journalArticle

Abstract

Aims: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). Methods: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. Results: Nineteen (40%) of the 47 tumours demonstrated positive (> 30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P = 0.039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. Conclusions: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC.

Original languageEnglish (US)
Pages (from-to)297-301
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume25
Issue number3
DOIs
StatePublished - Jun 1999
Externally publishedYes

Fingerprint

Bile Ducts
Carcinoma
Negative Staining
Neoplasms
Pancreaticoduodenectomy
Paraffin
Anti-Idiotypic Antibodies
Lymph Nodes
Survival
Incidence
Growth
Proteins

Keywords

  • Biliary cancer
  • Immunohistochemistry
  • p53
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Rijken, A. M., Offerhaus, G. J. A., Polak, M. M., Gouma, D. J., & Van Gulik, T. M. (1999). p53 expression as a prognostic determinant in resected distal bile duct carcinoma. European Journal of Surgical Oncology, 25(3), 297-301. https://doi.org/10.1053/ejso.1998.0645

p53 expression as a prognostic determinant in resected distal bile duct carcinoma. / Rijken, A. M.; Offerhaus, G. J A; Polak, M. M.; Gouma, D. J.; Van Gulik, T. M.

In: European Journal of Surgical Oncology, Vol. 25, No. 3, 06.1999, p. 297-301.

Research output: Contribution to journalArticle

Rijken, AM, Offerhaus, GJA, Polak, MM, Gouma, DJ & Van Gulik, TM 1999, 'p53 expression as a prognostic determinant in resected distal bile duct carcinoma', European Journal of Surgical Oncology, vol. 25, no. 3, pp. 297-301. https://doi.org/10.1053/ejso.1998.0645
Rijken, A. M. ; Offerhaus, G. J A ; Polak, M. M. ; Gouma, D. J. ; Van Gulik, T. M. / p53 expression as a prognostic determinant in resected distal bile duct carcinoma. In: European Journal of Surgical Oncology. 1999 ; Vol. 25, No. 3. pp. 297-301.
@article{961aa8df6dca48b78c9bfaf1a38dcfd7,
title = "p53 expression as a prognostic determinant in resected distal bile duct carcinoma",
abstract = "Aims: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). Methods: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. Results: Nineteen (40{\%}) of the 47 tumours demonstrated positive (> 30{\%}) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60{\%}) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P = 0.039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. Conclusions: This study indicates that low (0-30{\%}) p53 expression is a favourable prognostic factor in patients with resected DBDC.",
keywords = "Biliary cancer, Immunohistochemistry, p53, Prognosis",
author = "Rijken, {A. M.} and Offerhaus, {G. J A} and Polak, {M. M.} and Gouma, {D. J.} and {Van Gulik}, {T. M.}",
year = "1999",
month = "6",
doi = "10.1053/ejso.1998.0645",
language = "English (US)",
volume = "25",
pages = "297--301",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - p53 expression as a prognostic determinant in resected distal bile duct carcinoma

AU - Rijken, A. M.

AU - Offerhaus, G. J A

AU - Polak, M. M.

AU - Gouma, D. J.

AU - Van Gulik, T. M.

PY - 1999/6

Y1 - 1999/6

N2 - Aims: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). Methods: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. Results: Nineteen (40%) of the 47 tumours demonstrated positive (> 30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P = 0.039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. Conclusions: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC.

AB - Aims: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). Methods: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. Results: Nineteen (40%) of the 47 tumours demonstrated positive (> 30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P = 0.039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. Conclusions: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC.

KW - Biliary cancer

KW - Immunohistochemistry

KW - p53

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0033151676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033151676&partnerID=8YFLogxK

U2 - 10.1053/ejso.1998.0645

DO - 10.1053/ejso.1998.0645

M3 - Article

C2 - 10336811

AN - SCOPUS:0033151676

VL - 25

SP - 297

EP - 301

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 3

ER -